To encourage broad patient access to this important medicine, Mylan is offering Semglee at a wholesale acquisition cost (WAC)[1] of $147.98...

The product branded as Semglee has an identical amino acid sequence to Sanofi’s Lantus® and is approved for the same indications. This is t...

"We are extremely pleased with the US PTAB's ruling in favour of our partner Mylan for four device patents of Sanofi's Lantus SoloSTAR. Thi...

The biotech firm is also planning to provide its rh-insulin to middle- and low-income countries at less than 10 cents a day. Biocon Biologi...

Eye minority stake in Biocon Biologics; unit may be valued at $4 billion, higher than the market cap of Biocon.

Firms have been asked to share details about a change in the manufacturing site for glargine from Bengaluru to a new facility in Malaysia.

A Bloomberg report said two executives of Heritage Pharma – the US arm of Indian drug maker Emcure - are preparing to plead guilty to price...

Mylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.

We were second to enter the US in the marketing of a generic version of AstraZeneca's heartburn drug Nexium, but we still managed to build ...

Biocon today said two molecules for treating cancer and arthritis under the drug discovery programme with Mylan have entered global Phase 3...

This comes as a surprise as Sun has partnered the US based MSD in the domestic market to sue Glenmark for the patent infringement on the sa...

In 2009, Mylan and Biocon had come together to develop five blockbuster biologic drugs in cancer and pain areas.

Ranbaxy has launched authorized pioglitazone hydrochloride tablets, generic version of Takeda's diabetes drug sold under the brand Actos in...

The US drug regulator's refusal to allow Watson Pharma to launch generic version of diabetes drug could mean windfall for Ranbaxy, accordin...

Matrix Laboratories, which was acquired by Mylan , is exploring new partnerships in India to launch about 100 products.

Ranbaxy Laboratories Ltd on Monday said it has entered into an agreement with the Japanese drug maker Takeda Pharmaceuticals for ending the...

Biocon’s CMD Kiran Mazumdar Shaw is betting big on the oral insulin drug that the company is scheduled to unveil next March. She said the f...